Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: A single institutional experience

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 1, 2010, Pages 86-93

  Kim, Hee Seung ^a   Park, Noh Hyun ^a   Kang, Sokbom ^b   Seo, Sang Soo ^b   Chung, Hyun Hoon ^a   Kim, Jae Weon ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Belotecan; Epithelial ovarian cancer; Recurrent; Topotecan

Indexed keywords

BELOTECAN; CA 125 ANTIGEN; CAMPTOBELL; CISPLATIN; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EPITHELIAL OVARIAN CANCER; EPITHELIUM TUMOR; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CISPLATIN; EPITHELIUM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 76349120586     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2009.01101.x     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 : 106 130.
2. Kim K, Kim JW, Kang SB. Major clinical research advances in gynecologic cancer 2007. J Gynecol Oncol 2008 19 : 1 8.
3. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003 21 : 3194 3200.
4. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 9 : 389 393.
5. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996 63 : 89 93.
6. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997 15 : 987 993.
7. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994 12 : 60 63.
8. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998 16 : 2233 2237.
9. Crul M. CKD-602. Chong Kun Dang. Curr Opin Investig Drugs 2003 4 : 1455 1459.
10. Park IS, Ahn MR, Suh SK et al. In vitro pharmacodynamics of CKD-602 in HT-29 cells. Arch Pharm Res 2002 25 : 718 723.
11. Lee JH, Lee JM, Kim JK et al. Antitumor activity of 7-[2-(N- isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998 21 : 581 590.
12. Lee JH, Lee JM, Lim KH et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 2000 922 : 324 325.
13. Lee HP, Seo SS, Ryu SY et al. Phase II evaluation of CKD-602, a camptotecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 2008 109 : 359 363.
14. Kim HS, Kang S, Seo SS et al. Phase I/IIa study of combination chemotherapy with CKO-602 and cisplatin in patients with recurrent epithelial ovarian cancer. Ann N Y Acad Sci 2009 1171 : 627 634.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 216.
16. Panici PB, Maggioni A, Hacker N et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst 2005 97 : 560 566. (Pubitemid 40723783)
17. Ayhan A, Taskiran C, Yigit-Celik N et al. Topotecan as a second-line therapy in patients with ovarian and primary peritoneal cancer: Initial response and long-term follow-up. Eur J Gynaecol Oncol 2006 27 : 603 606.
18. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998 16 : 3345 3352.
19. Ghamande SA, Piver MS. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study. J Surg Oncol 1999 72 : 162 166.